Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers

Bulbulgul Aumakhan, Charlotte A. Gaydos, Thomas C. Quinn, Chris Beyrer, Lorie Benning, Howard Minkoff, Daniel J. Merenstein, Mardge Cohen, Ruth Greenblatt, Marek Nowicki, Kathryn Anastos, Stephen J. Gange

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The natural history of HSV-2 infection and role of HSV-2 reactivations in HIV disease progression are unclear. Methods: Clinical symptoms of active HSV-2 infection were used to classify 1,938 HIV/HSV-2 co-infected participants of the Women's Interagency HIV Study (WIHS) into groups of varying degree of HSV-2 clinical activity. Differences in plasma HIV RNA and CD4+ T cell counts between groups were explored longitudinally across three study visits and cross-sectionally at the last study visit. Results: A dose dependent association between markers of HIV disease progression and degree of HSV-2 clinical activity was observed. In multivariate analyses after adjusting for baseline CD4+ T cell levels, active HSV-2 infection with frequent symptomatic reactivations was associated with 21% to 32% increase in the probability of detectable plasma HIV RNA (trend p = 0.004), an average of 0.27 to 0.29 log10 copies/ml higher plasma HIV RNA on a continuous scale (trend p<0.001) and 51 to 101 reduced CD4+ T cells/mm3 over time compared to asymptomatic HSV-2 infection (trend p<0.001). Conclusions: HIV induced CD4+ T cell loss was associated with frequent symptomatic HSV-2 reactivations. However, effect of HSV-2 reactivations on HIV disease progression markers in this population was modest and appears to be dependent on the frequency and severity of reactivations. Further studies will be necessary to determine whether HSV-2 reactivations contribute to acceleration of HIV disease progression.

Original languageEnglish (US)
Article numbere9973
JournalPLoS One
Volume5
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Human herpesvirus 2
Human Herpesvirus 2
T-cells
Human immunodeficiency virus
Virus Diseases
Viruses
disease course
Disease Progression
T-lymphocytes
HIV
RNA
Plasmas
infection
natural history
T-Lymphocytes
Infection
dosage
HIV-2
CD4 Lymphocyte Count
Natural History

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Aumakhan, B., Gaydos, C. A., Quinn, T. C., Beyrer, C., Benning, L., Minkoff, H., ... Gange, S. J. (2010). Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One, 5(4), [e9973]. https://doi.org/10.1371/journal.pone.0009973

Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. / Aumakhan, Bulbulgul; Gaydos, Charlotte A.; Quinn, Thomas C.; Beyrer, Chris; Benning, Lorie; Minkoff, Howard; Merenstein, Daniel J.; Cohen, Mardge; Greenblatt, Ruth; Nowicki, Marek; Anastos, Kathryn; Gange, Stephen J.

In: PLoS One, Vol. 5, No. 4, e9973, 2010.

Research output: Contribution to journalArticle

Aumakhan, B, Gaydos, CA, Quinn, TC, Beyrer, C, Benning, L, Minkoff, H, Merenstein, DJ, Cohen, M, Greenblatt, R, Nowicki, M, Anastos, K & Gange, SJ 2010, 'Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers', PLoS One, vol. 5, no. 4, e9973. https://doi.org/10.1371/journal.pone.0009973
Aumakhan, Bulbulgul ; Gaydos, Charlotte A. ; Quinn, Thomas C. ; Beyrer, Chris ; Benning, Lorie ; Minkoff, Howard ; Merenstein, Daniel J. ; Cohen, Mardge ; Greenblatt, Ruth ; Nowicki, Marek ; Anastos, Kathryn ; Gange, Stephen J. / Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. In: PLoS One. 2010 ; Vol. 5, No. 4.
@article{aa324bb7448e46c18e72da02d3bb6a4c,
title = "Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers",
abstract = "Background: The natural history of HSV-2 infection and role of HSV-2 reactivations in HIV disease progression are unclear. Methods: Clinical symptoms of active HSV-2 infection were used to classify 1,938 HIV/HSV-2 co-infected participants of the Women's Interagency HIV Study (WIHS) into groups of varying degree of HSV-2 clinical activity. Differences in plasma HIV RNA and CD4+ T cell counts between groups were explored longitudinally across three study visits and cross-sectionally at the last study visit. Results: A dose dependent association between markers of HIV disease progression and degree of HSV-2 clinical activity was observed. In multivariate analyses after adjusting for baseline CD4+ T cell levels, active HSV-2 infection with frequent symptomatic reactivations was associated with 21{\%} to 32{\%} increase in the probability of detectable plasma HIV RNA (trend p = 0.004), an average of 0.27 to 0.29 log10 copies/ml higher plasma HIV RNA on a continuous scale (trend p<0.001) and 51 to 101 reduced CD4+ T cells/mm3 over time compared to asymptomatic HSV-2 infection (trend p<0.001). Conclusions: HIV induced CD4+ T cell loss was associated with frequent symptomatic HSV-2 reactivations. However, effect of HSV-2 reactivations on HIV disease progression markers in this population was modest and appears to be dependent on the frequency and severity of reactivations. Further studies will be necessary to determine whether HSV-2 reactivations contribute to acceleration of HIV disease progression.",
author = "Bulbulgul Aumakhan and Gaydos, {Charlotte A.} and Quinn, {Thomas C.} and Chris Beyrer and Lorie Benning and Howard Minkoff and Merenstein, {Daniel J.} and Mardge Cohen and Ruth Greenblatt and Marek Nowicki and Kathryn Anastos and Gange, {Stephen J.}",
year = "2010",
doi = "10.1371/journal.pone.0009973",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers

AU - Aumakhan, Bulbulgul

AU - Gaydos, Charlotte A.

AU - Quinn, Thomas C.

AU - Beyrer, Chris

AU - Benning, Lorie

AU - Minkoff, Howard

AU - Merenstein, Daniel J.

AU - Cohen, Mardge

AU - Greenblatt, Ruth

AU - Nowicki, Marek

AU - Anastos, Kathryn

AU - Gange, Stephen J.

PY - 2010

Y1 - 2010

N2 - Background: The natural history of HSV-2 infection and role of HSV-2 reactivations in HIV disease progression are unclear. Methods: Clinical symptoms of active HSV-2 infection were used to classify 1,938 HIV/HSV-2 co-infected participants of the Women's Interagency HIV Study (WIHS) into groups of varying degree of HSV-2 clinical activity. Differences in plasma HIV RNA and CD4+ T cell counts between groups were explored longitudinally across three study visits and cross-sectionally at the last study visit. Results: A dose dependent association between markers of HIV disease progression and degree of HSV-2 clinical activity was observed. In multivariate analyses after adjusting for baseline CD4+ T cell levels, active HSV-2 infection with frequent symptomatic reactivations was associated with 21% to 32% increase in the probability of detectable plasma HIV RNA (trend p = 0.004), an average of 0.27 to 0.29 log10 copies/ml higher plasma HIV RNA on a continuous scale (trend p<0.001) and 51 to 101 reduced CD4+ T cells/mm3 over time compared to asymptomatic HSV-2 infection (trend p<0.001). Conclusions: HIV induced CD4+ T cell loss was associated with frequent symptomatic HSV-2 reactivations. However, effect of HSV-2 reactivations on HIV disease progression markers in this population was modest and appears to be dependent on the frequency and severity of reactivations. Further studies will be necessary to determine whether HSV-2 reactivations contribute to acceleration of HIV disease progression.

AB - Background: The natural history of HSV-2 infection and role of HSV-2 reactivations in HIV disease progression are unclear. Methods: Clinical symptoms of active HSV-2 infection were used to classify 1,938 HIV/HSV-2 co-infected participants of the Women's Interagency HIV Study (WIHS) into groups of varying degree of HSV-2 clinical activity. Differences in plasma HIV RNA and CD4+ T cell counts between groups were explored longitudinally across three study visits and cross-sectionally at the last study visit. Results: A dose dependent association between markers of HIV disease progression and degree of HSV-2 clinical activity was observed. In multivariate analyses after adjusting for baseline CD4+ T cell levels, active HSV-2 infection with frequent symptomatic reactivations was associated with 21% to 32% increase in the probability of detectable plasma HIV RNA (trend p = 0.004), an average of 0.27 to 0.29 log10 copies/ml higher plasma HIV RNA on a continuous scale (trend p<0.001) and 51 to 101 reduced CD4+ T cells/mm3 over time compared to asymptomatic HSV-2 infection (trend p<0.001). Conclusions: HIV induced CD4+ T cell loss was associated with frequent symptomatic HSV-2 reactivations. However, effect of HSV-2 reactivations on HIV disease progression markers in this population was modest and appears to be dependent on the frequency and severity of reactivations. Further studies will be necessary to determine whether HSV-2 reactivations contribute to acceleration of HIV disease progression.

UR - http://www.scopus.com/inward/record.url?scp=77956332703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956332703&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0009973

DO - 10.1371/journal.pone.0009973

M3 - Article

C2 - 20376310

AN - SCOPUS:77956332703

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e9973

ER -